Health Care • Biotechnology: Pharmaceutical Preparations
$4.93 ▼ -0.17
(-3.33%)
MKT CAP: $8.8M • VOL: 12.2K
52W L $5 52W H $31
ROARABLE / RQD
D- • 38/100
PIOTROSKI
1 / 9
PTN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $4.5M | $4.9M |
| YoY Revenue Growth % | — | -7.5% | — |
| Gross Profit | — | $4.4M | — |
| Gross Margin % | — | 97.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$17.5M | -$22.5M | -$32.5M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | -$17.3M | $29.7M | $36.2M |
| EBITDA (Normalized) | -$17.5M | -$22.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$21.3M | -$31.5M | -$29.3M |
| Capital Expenditures (CapEx) | $0 | $42.5K | — |
| Free Cash Flow (FCF) | -$21.3M | -$31.5M | -$29.3M |
| FCF Margin % | — | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $14.5M | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $11.5M | -$6.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PTN.